Showing results (71-80 of 89) with videos related to

Sort By:
Pageof 9
European Journal of Drug Metabolism and Pharmacokinetics|December 4, 2014
Safety and pharmacokinetics of the CIME combination of drugs and their metabolites after a single oral dosing in healthy volunteersNatacha Lenuzza, Xavier Duval, Grégory Nicolas, et al.
Biochimie|August 11, 2022
Imbalance between alpha-1-antitrypsin and interleukin 6 is associated with in-hospital mortality and thrombosis during COVID-19Aurélien Philippe, Mathilde Puel, Céline Narjoz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2010
Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05Valérie Boige, Jean Mendiboure, Jean-Pierre Pignon, et al.
Clinical Pharmacology and Therapeutics|April 30, 2004
Pharmacogenetics of acenocoumarol pharmacodynamicsSandrine Morin, Laurent Bodin, Marie-Anne Loriot, et al.
Therapie|January 9, 2025
How to facilitate the wider use of pharmacogenetic tests?Céline Verstuyft, Dominique Dewolf, Olivier Blin, et al.
Inflammatory Bowel Diseases|January 9, 2007
Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine A in patients with steroid resistant ulcerative colitisFady Daniel, Marie-Anne Loriot, Philippe Seksik, et al.
Molecular Cancer Therapeutics|October 24, 2015
High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 StudySylvain Manfredi, Olivier Bouché, Philippe Rougier, et al.
Bulletin Du Cancer|July 1, 2014
[Interest of UGT1A1 genotyping within digestive cancers treatment by irinotecan]Jean-Christophe Boyer, Marie-Christine Etienne-Grimaldi, Fabienne Thomas, et al.
Drug Design, Development and Therapy|August 27, 2019
Dextromethorphan and memantine after ketamine analgesia: a randomized control trialElodie Martin, Marc Sorel, Véronique Morel, et al.
Therapeutic Drug Monitoring|February 2, 2016
A Lack of Significant Effect of POR*28 Allelic Variant on Tacrolimus Exposure in Kidney Transplant RecipientsAnne-Sophie Jannot, Xavier Vuillemin, Isabelle Etienne, et al.
Pageof 9